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Summary Studies carried out over the last decade have strongly suggested that TNFa both overtly participates in the cell-mediated immune response against Mycobacterium ieprae, and is overproduced during reaction. In addition, reactions are intimately related to the onset of nerve damage. Finally, TNFa has been implicated in the pathogenesis of many human and experimental autoimmune peripheral neuropathies that, as in leprosy, result in demyelination and axonal lesions. Because of recent findings associating human TNFa mutant alleles at the -308 position with increased production of TNFa in many immunological and infectious diseases, an investigation of the role of TNF2 in predisposing leprosy patients to reaction has been undertaken. Analysis of 300 patients with leprosy-2 10 multi bacillary and 90 paucibacillary-has shown that the percentage of reactional patients was similar among both carriers and non-carriers of the TNF2 allele. However, a separate analysis of 57 carriers of TNF2 found that reactions occurred much more frequently among heterozygous than among homozygous patients. Moreover, the frequency of neuritis was somewhat greater among the heterozygous patients than among the non-carriers. Enhanced serum levels of TNFa have been noted in both TNF-l and TNF-2 mutant patients in the course of leprosy reaction. Our observations to date suggest that other factors not related to the presence of the mutant gene may lead to the TNFa hyper-responsiveness observed during reaction.
Human TNPex, also known as cache tin, is a cytokine that exhibits wide-ranging biological activities and systemic effects, including protection against infection, surveillance against tumours, and stimulation of inflammatory responses, in addition to mediation of septic shock in chronic infection and cachexia in cancer patients. TNPex has also been shown to be capable of directly causing the destruction of myelin and oligodendrocytes in vitro. I Because overproduction of TNFex has been shown to be deleterious to the host, leading to irreversible organ failure and death, both the beneficial and negative effects of this cytokine require that stringent controls be imposed on its synthesis. Consequently, TNFex gene expression must be tightly regulated. 2 Regulation of the production of TNFex occurs at both the transcriptional and post-transcriptional levels; because the rate of transcription is an important regulator of production, it has been suggested that, in certain situations, variations within the regulatory regions of the TNFa gene contribute to alterations of cytokine-expression. Moreover, linkage between mutations in the TNF promoter region and development of acute inflammatory complications during the course of some diseases has been clearly established, the prime example being cerebral malaria. 3 It has been shown that a single base polymorphism within the promoter region may alter the rates of both gene transcription and protein production. To date, 13 different allelic variations have been found to exist in the promoter region of the TNFa gene. Because all of these variations appear to be located within the limits of the gene's regulatory region, determination of the association of these variations with expression of TNFa, as well as with disease, remains an important area of study.
A biallelic polymorphism, consisting of a G versus A transition at position -308 (TNF2) of the TNFa promoter, although not apparently related to any currently recognised DNA-binding protein sequence motif, appears to be directly involved in the alteration of TNFa gene expression. 4 Several studies of the role of this mutation in production of TNFa, although contradictory, 5 , 6 have shown, in support of a predisposing effect, 4 , 7 the TNF2 allele to be associated with higher constitutive and inducible levels of transcription compared to the wild type allele (TNFl). Moreover, a relationship between the presence of the TNF2 allele and disease has also been detected in mucocutaneous leishmaniasis, 8 meningococcal disease, 9 and lepromatous leprosy, 1 0
Studies carried out during the last decade by our group and others have strongly suggested that: (i) TNFa both overtly participates in the cell-mediated immune response against M. Zeprae, and is overproduced during reaction; 11 , 1 2 (ii) reactions are intimately related to the onset of nerve damage; 13 , 1 4 and (iii) TNFa has been implicated in the pathogenesis of many human and experimental autoimmune peripheral neuropathies that, as is the case in leprosy,
15 16 resu t m emye mahon an axona eSlOns. ' Because of recent findings associating the human TNFa mutant alleles at the -308 position (individuals carrying AA or GA instead of GG) to the increased production of TNFa . in immunological and infectious diseases, we decided to investigate the role of TNF2 in predisposing leprosy patients to reaction and nerve damage.
Materials and methods
To date, 300 leprosy patients classified according to Ridley and Jopling, 1 7 covering the entire clinical spectrum [2 10 multibacillary (MB) and 90 paucibacillary (PB) patients], and 92 controls have been typed for the -308 mutation.
Genomic DNA was prepared from frozen whole blood (300 ILl) by a commercially available DNA extraction kit (Gibco BRL, Gaithersburg, MD, USA). Typing of the TNFa promoter region (107 bp fr agment) for analysis of polymorphisms at the -308 position was performed with the aid of specific primers through a single peR step and further digestion with NcoI. 2 0
Determination of the quantity of TNFa protein in the sera of patients at the time leprosy was diagnosed (non-reactional patients; n = 33) and during a reaction [either erythema nodosum leprosum (ENL), reversal reaction (RR), or neuritis; n = 29] was performed by ELISA (Innogenetics N.V., Gent, Belgium) and processed according to the manufacturer's instructions.
Results
Preliminary analyses of this population showed a significantly (i = 7'55, P = 0'005) higher frequency of the mutant allele among healthy individuals (16'3%) than among leprosy patients (lO'8%), suggesting that the presence of the TNF2 allele protects against the development of the more severe formes) of leprosy. 1 8 Analysis of the occurrence of reactions in this group of leprosy patients showed that the proportion of patients with reaction was similar among carriers (61 '4%) and non-carriers (69%) of the TNF2 allele. There was no difference of frequency of the genotype between patients with reaction and those without. The frequency of TNFI was a little greater among patients with ENL, whereas TNF2 was slightly more frequent among patients presenting neuritis.
The relationship of the -308 mutant allele to clinical diagnosis and type of reaction among the 203 reactional patients (174 MB and 29 PB) is shown in Figure 1 . Analysis of the TNF2 carriers (n = 57) demonstrated that reactions were much more frequent among the heterozygous (65'3%) than among the homozygous (37'5%) patients. Moreover, the frequency of neuritis was somewhat greater among the heterozygous patients than among the non-carriers (37'1 % versus 26'2%, respectively).
Detection of TNFa protein by ELISA was assessed in the sera of the same patients, 41 of whom were TNFI and 21 TNF2, at diagnosis and during reaction. Enhanced TNFa levels have been noted in both TNF-l and TNF-2 mutant patients in the course of reaction (see Figure 2 ). Mean levels of TNFa were similar for both TNFI and TNF2 patients in the absence of, as well as during, reaction; and both TNFI and TNF2 patients showed increased TNFa levels during reaction. Thus far, our data suggest that other factors, not exclusively related to the presence of the mutant gene, may be responsible for the hyper-responsiveness to TNFa observed during the reaction. This study ofTNFcx polymorphism indicates that, in addition to the primary association of ,.
the mutant allele with PB leprosy, 18 there may also be an association with the occurrence of neuritis, especially in the PB form of the disease. However, demonstrating an association between the TNF genotypes and the serum TNFcx levels has proven to be a very difficult task.
The identification of genetic markers for susceptibility to, or severity of, inflammatory reactions is a goal to be pursued in leprosy and several other diseases. Even so, one of the greatest challenges facing scientists today is the integration of the myriad components of the organism in such a way as to clarify its functioning as a whole, as well as that of its Professor Brennan: I've been thinking about the nature of the bacterial stimulus to reactions and nerve damage. We have heard that one of the predictors is MB leprosy; this implies the importance, at some time in the process, of the size of the bacterial burden and the presence of bacterial products. What might these products be? One thinks of rather odd molecules that can withstand natural degradative processes, thus eliminating peptides. One such substance is lipoarabinomannan (LAM). M. leprae produces it in massive quantities, and mammals lack the glycosidases needed to degrade this material. We've heard from Drs Kaplan, Lockwood and Nath about the roles of certain cytokines in pathogenesis; there is some evidence that LAM stimulates production of TNFex and others of these cytokines. Assays exist for LAM and similar molecules. If one could demonstrate a relationship between the presence of LAM, for example, and nerve damage, then one could begin to consider means of clearing these materials.
Dr Lockwood: We have identified LAM in nerve biopsy specimens obtained from patients in reaction.
Professor Britton:
One might wonder what are the metabolic effects of LAM within the Schwann cell. Once the Schwann cell has been injured, axonal damage is inevitable. The issue of metabolic effects in the Schwann cell might be a fruitful area for research.
Dr Gupte: I wonder if the area of surgical treatment of nerve damage has been sufficiently investigated. The literature contains some evidence of the efficacy of surgical decompression of inflamed nerves, for example.
Professor Smith: Do you feel that the evidence is sufficiently promising to justify further research?
Dr Gupte : Yes, I believe it is. Dr Lockwood: I believe there is an urgent need for a trial of decompression vs. steroids. Many surgeons currently perform decompressions on patients being treated with steroids. A number of manuscripts have been submitted to Leprosy Review, in which it has been very difficult to distinguish between the effects of surgery and those of steroids.
Dr van Brakel: A surgical colleague who worked in Nepal in the past has already prepared a protocol for such a trial.
Professor ii: Surgical decompression has been commonly used in some countries. I agree that the efficacy of decompression should be determined. However, I don't think a clinical trial is justified; I believe that all patients must first receive steroids. Perhaps, if improvement following therapy with steroids is insufficient, then one might consider decompression, among other alternatives.
Dr Nunn: Estimates of the burden of a disease have been quite useful in determining priorities, particularly when one must choose between diseases. Are you satisfied that the currently available methods of measuring disability resulting from leprosy are accurate? The DALY (Disability-Adjusted Life Years) score of leprosy is by far the smallest of all ten diseases included in TDR (the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases).
Professor Smith: I think we're quite good at measuring physical impairments, but not disabilities and handicaps and the social consequences of these.
Dr Rambukkana: It would be good if we could remove the organisms from the Schwann cells. Even irradiated M. leprae can produce considerable damage to Schwann cells. This could account for the progression of nerve damage after MDT.
